DE69532701D1 - BR96 mutant antibodies that react with human carcinomas - Google Patents

BR96 mutant antibodies that react with human carcinomas

Info

Publication number
DE69532701D1
DE69532701D1 DE69532701T DE69532701T DE69532701D1 DE 69532701 D1 DE69532701 D1 DE 69532701D1 DE 69532701 T DE69532701 T DE 69532701T DE 69532701 T DE69532701 T DE 69532701T DE 69532701 D1 DE69532701 D1 DE 69532701D1
Authority
DE
Germany
Prior art keywords
react
mutant antibodies
human carcinomas
variable region
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69532701T
Other languages
German (de)
Inventor
Dale Yelton
Scott Glaser
William Huse
Mae Joanne Rosok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/285,936 external-priority patent/US5728821A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE69532701D1 publication Critical patent/DE69532701D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention provides mutant BR96 polypeptides (and nucleotide sequences encoding them) having a variable region comprising an amino acid sequence substantially homologous to the variable region of BR96. <MATH>
DE69532701T 1994-08-04 1995-08-03 BR96 mutant antibodies that react with human carcinomas Expired - Lifetime DE69532701D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/285,936 US5728821A (en) 1994-08-04 1994-08-04 Mutant BR96 antibodies reactive with human carcinomas
US08/487,860 US5792456A (en) 1994-08-04 1995-06-07 Mutant BR96 antibodies reactive with human carcinomas

Publications (1)

Publication Number Publication Date
DE69532701D1 true DE69532701D1 (en) 2004-04-22

Family

ID=26963478

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532701T Expired - Lifetime DE69532701D1 (en) 1994-08-04 1995-08-03 BR96 mutant antibodies that react with human carcinomas

Country Status (9)

Country Link
US (1) US5792456A (en)
EP (1) EP0699756B1 (en)
JP (1) JPH08191692A (en)
AT (1) ATE262038T1 (en)
AU (1) AU2834995A (en)
CA (1) CA2155397A1 (en)
DE (1) DE69532701D1 (en)
IL (1) IL114809A0 (en)
MX (1) MX9503362A (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
US7247302B1 (en) * 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
AU3968897A (en) * 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
ATE290205T1 (en) 1996-12-12 2005-03-15 Prolume Ltd DEVICE AND METHOD FOR DETECTING AND IDENTIFYING INFECTIOUS ACTIVE SUBSTANCES
EP1007967A2 (en) * 1997-08-04 2000-06-14 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6656467B2 (en) 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
DK1259547T3 (en) 2000-03-01 2012-10-15 Medimmune Inc HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP2005502645A (en) * 2001-08-08 2005-01-27 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Method for amplifying expression from a cell-specific promoter
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AT413487B (en) * 2002-08-12 2006-03-15 Igeneon Krebs Immuntherapie USE OF ANTIBODIES TO TUMOR ASSOCIATED ANTIGEN
JP4462964B2 (en) * 2003-03-10 2010-05-12 第一三共株式会社 Antibodies targeting cancer-specific antigens
AR048098A1 (en) * 2004-03-15 2006-03-29 Wyeth Corp CALIQUEAMYCIN CONJUGATES
EP1943332A4 (en) * 2005-10-14 2011-04-13 Medimmune Inc Cell display of antibody libraries
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
BR112015020885A2 (en) 2013-03-11 2017-10-10 Genzyme Corp hyperglycosylated binding polypeptides
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
SG11202010025YA (en) 2018-05-31 2020-11-27 Glyconex Inc Therapeutic antibodies binding to biantennary lewis b and lewis y antigens

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4713352A (en) * 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4612282A (en) * 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4507391A (en) * 1982-04-02 1985-03-26 Sloan-Kettering Institute For Cancer Research Method for detecting the presence of GD3 ganglioside
US4713351A (en) * 1983-01-28 1987-12-15 The University Of Rochester Monoclonal antibody directed to an antigen derived from human ovarian tumors and a radioimmunoassay using the antibody
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
ZA858371B (en) * 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
PT89107A (en) * 1987-11-30 1989-11-30 Idec Pharma Corp METHOD AND MEANS FOR THE SELECTION OF ANTI-IDIOTIPOSAL ANTIBODIES AND THEIR USE FOR DIAGNOSIS, MONITORING, TREATMENT AND / OR PREVENTION OF CANCER, AUTOMOBILE, OR INFECTIOUS DISEASES
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
JPH06501705A (en) * 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー Synergistic treatment with a combination of anti-tumor antibodies and biologically active agents
ATE239506T1 (en) * 1992-03-05 2003-05-15 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS

Also Published As

Publication number Publication date
US5792456A (en) 1998-08-11
IL114809A0 (en) 1995-12-08
JPH08191692A (en) 1996-07-30
CA2155397A1 (en) 1996-02-05
ATE262038T1 (en) 2004-04-15
MX9503362A (en) 1997-08-30
AU2834995A (en) 1996-02-15
EP0699756A1 (en) 1996-03-06
EP0699756B1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
DE69532701D1 (en) BR96 mutant antibodies that react with human carcinomas
GB9828628D0 (en) Novel ligand
CA2079881A1 (en) Nucleotidic sequences coding for variable regions of .beta. chains of human t lymphocite receptors, corresponding peptidic segments and diagnostic and therapeutic applications
NO980255D0 (en) Antiparasitic marc fortines and paraherquamides
EP0886644A4 (en) Long wavelength engineered fluorescent proteins
EP2270047A3 (en) Anti-C5 antibodies and their therapeutic uses
NZ503850A (en) April - a novel protein with growth effects
DK0839196T3 (en) Human CTLA-8 and uses of CTLA-8-related proteins
GR3030811T3 (en) Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
DE69133593D1 (en) Human CNP gene and precursor protein
HUT77049A (en) Cathepsin 02 protease
EP0255011A3 (en) Human inter-alpha-trypsin inhibitor gene
NZ292565A (en) Production of stabilised complement protein-3 convertase
ATE339878T1 (en) MYC-BINDING ZINC FINGER PROTEINS, THEIR PRODUCTION AND THEIR USE
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
FR2692282B1 (en) CLONING OF THE GENE ENCODING THE PROTEIN GP28.5 OF T. GONDII; PEPTIDE FRAGMENTS FROM SUCH PROTEIN AND THEIR APPLICATIONS.
DE3582136D1 (en) GEN FOR A PROTEIN WITH INSECTICIDAL EFFECT.
DE3377220D1 (en) Recombinant dna, microorganism transformed therewith and use thereof
GB9416536D0 (en) Orphan receptor
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
WO2000029564A3 (en) Human glycine transporter type 2
CA2199843A1 (en) Novel PKA-Binding Proteins and Uses Thereof
TW342413B (en) Novel toxins isolated from Bracon Hebetor
DE69613086D1 (en) Antigenic peptides with glycine substitution

Legal Events

Date Code Title Description
8332 No legal effect for de